Lantheus Holdings

NASDAQ: LNTH ↗$101.08 USD~$8B (acquisition by Curium) MCAP

#Oncology imaging #Cardiology imaging #Radiopharmaceuticals

Radiopharmaceutical company behind PYLARIFY (PSMA PET imaging), Definity ultrasound contrast and TechneLite; agreed to be acquired by Curium for ~$8B in 2026.

Company Info

Sector:Radiopharmaceuticals

Headquarters:Bedford, Massachusetts, USA

Founded:1956

Website:www.lantheus.com/

Upcoming Milestones & Key Dates

2026 H2

Corporate

Expected close of Curium acquisition (~$8B)

Clinical Development Pipeline

PYLARIFY (piflufolastat F 18)

Target: PSMA-targeted PET tracer

Prostate cancer PET imaging

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Definity

Target: Perflutren lipid microsphere

Ultrasound contrast

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Curium buys Lantheus for $8B; Sandoz settles price-fixing cases ↗

Curium acquires Lantheus for $102.5/share (~$8B); Sandoz settles price-fixing claims for $478.5M; Latigo eyes a $247M IPO for non-opioid LTG-001; BlossomHill targets a $111M IPO.

Leadership Team

Brian Markison

Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →